var data={"title":"Ioflupane I-123: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ioflupane I-123: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/476011?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ioflupane-i-123-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ioflupane I-123: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374859\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>DaTscan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374863\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374916\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Thyroid protective agents (potassium iodide [SSKI] or Lugol solution) equivalent to 100 mg iodide or 400 mg potassium perchlorate, should be given at least 1 hour prior to ioflupane I123 administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Brain imaging:</b> IV: 3 to 5 mCi (111 to 185 MBq); perform SPECT imaging 3 to 6 hours after ioflupane I 123 administration (refer to manufacturer&rsquo;s prescribing information for additional imaging information).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374917\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374919\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. <b>Note:</b> Ioflupane I 123 is renally excreted and patients with severe renal impairment may have increased radiation exposure and altered SPECT images.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374918\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosages adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374925\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DaTscan: 185 MBq/2.5 mL (2.5 mL) [pyrogen free; contains alcohol, usp]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374861\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374920\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer by slow IV injection over at least 15 to 20 seconds via an arm vein. Begin SPECT imaging 3 to 6 hours following IV administration; refer to manufacturer&rsquo;s prescribing information for additional imaging information. Ensure adequate hydration before and after administration; void frequently for the first 48 hours post administration to minimize bladder exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374864\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Brain imaging:</b> Striatal dopamine transporter (DaT) visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15245846\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374899\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&le;1%, postmarketing, and/or case reports: Dizziness, headache, nausea, pruritus, skin rash, vertigo, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374883\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to ioflupane I123 or any components of the formulation, or to iodine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374884\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions have been reported. Use extreme caution in patients with iodine or iodine contrast agent hypersensitivity. Appropriate equipment and emergency medications should be available during use. Hypersensitivity reactions primarily involved skin erythema and/or pruritus; reactions usually resolved spontaneously or following administration of corticosteroids and antihistamines. Monitor for signs/symptoms of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; ioflupane I 123 is eliminated renally. Therefore, patients with severe renal impairment may have increased radiation exposure and altered images. Effect of renal impairment on imaging with ioflupane I 123 has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and shielding to minimize exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To limit thyroid gland accumulation of iodine 123 during exposure to ioflupane I 123, administer thyroid-blocking medications (eg, potassium iodide oral solutions, potassium perchlorate) at least 1 hour prior to administration; increased long-term risk for thyroid neoplasia can occur from failure to block thyroid uptake of iodine 123. <b>Note:</b> Avoid the use of potassium iodide oral solution or Lugol solution in patients with past hypersensitivity to iodine or iodide products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder exposure: Patients should be adequately hydrated prior to and following administration; instruct patients to void frequently for 48 hours following administration to decrease radiation exposure to bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13462055\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13462053\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17072&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amoxapine: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benztropine: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norepinephrine: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the diagnostic effect of Ioflupane I 123.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374879\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374880\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm and pregnancy should be ruled out prior to administration in women of reproductive age. Radioactive iodine crosses the placenta and may impair fetal thyroid function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374882\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The radiolabeled component of ioflupane, iodine 123, is excreted into human milk, therefore, due to potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. Consider interrupting breast-feeding (pumping and discarding) for 6 days after administration of ioflupane I 123 to minimize risk to infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374923\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs/symptoms of hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374905\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to dopamine transporter (DaT) in brain allowing for visualization of regions of interest in the brain to aid in the diagnosis of Parkinsonian syndromes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13374907\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> DaTscan contains iodine-123 labeled ioflupane. The kinetics of the drug molecule ioflupane are not equivalent to the kinetics/half-life of  the radiolabeled ioflupane iodine 123. The kinetics presented correspond to the radioactive ioflupane I 123.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Uptake in the brain reached ~7% at 10 minutes after administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of radioactivity: Uptake in the brain reached ~3% after 5 hours. Striata to background ratios were constant between 3 to 6 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~30% of radioactivity from the whole brain attributed to striatal uptake</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Iodine 123: 13.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: At 48 hours postinjection: Urine (~60% ); fecal (~14%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322907\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DaTscan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">185 mbq/2.5 mL (2.5 mL): $2,961.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059494\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>DaTSCAN (AT, DK, ES, HR, HU, IE, LU, NO, PL, PT, SI);</li>\n      <li>Datscan (CH, CZ, EE, FR, IL, IS, JP, LT, MT, NL, RO, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    DaTscan (iofluplane I 123) [prescribing information]. Arlington Heights, IL: GE Healthcare/Medi-Physics Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tolosa E, Borght TV, and Moreno E, &ldquo;Accuracy of DaTSCAN (123I-Ioflupane) SPECT in Diagnosis of Patients With Clinically Uncertain Parkinsonism: 2-Year Follow-Up of an Open-Label Study,&rdquo; <i>Mov Disord</i>, 2007, 22(16):2346-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioflupane-i-123-drug-information/abstract-text/17914722/pubmed\" target=\"_blank\" id=\"17914722\">17914722</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17072 Version 61.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13374859\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13374863\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13374916\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F13374917\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13374919\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13374918\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13374925\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13374861\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13374920\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13374864\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15245846\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13374899\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13374883\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13374884\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13462055\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13462053\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13374879\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13374880\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13374882\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13374923\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13374905\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13374907\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322907\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059494\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17072|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ioflupane-i-123-patient-drug-information\" class=\"drug drug_patient\">Ioflupane I-123: Patient drug information</a></li></ul></div></div>","javascript":null}